Overview

NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With Autoimmune Disease (Ntrust-1)

Status:
RECRUITING

Trial end date:
2027-04-01

Target enrollment:

Participant gender:

Summary

This is an open-label, multi-center, non-randomized Phase 1 study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with active lupus nephritis (LN) or primary membranous nephropathy (pMN).

Phase:

PHASE1

Details

Lead Sponsor:

Nkarta, Inc.

Treatments:

Cyclophosphamide
fludarabine